Infant Data
Results
INDICATIONS
Sedative/hypnotic, for short-term use.
ADVERSE EFFECTS
Respiratory depression. Tolerance, dependence, and cardiovascular depression occur with continued use. Enhances metabolism of phenytoin, sodium valproate, and corticosteroids by microsomal enzyme induction.
ADMINISTRATION
Intravenous: For sedation doses, administer IV over 30 seconds to 2 minutes undiluted (50 mg/mL). May dilute to 5 mg/mL.
BLACK BOX WARNING
There are serious risks, including profound sedation, respiratory depression, coma, and/or death, associated with combined use of opioids and benzodiazepines, other drugs that depress the CNS, or alcohol. Concomitant use should be reserved for patients with no alternative treatment. If necessary, use the lowest initial dose and titrate based on clinical response. Monitor patients closely for sedation and respiratory depression. Screen patients for risk of substance-use disorders.
MONITORING
Monitor respiratory status and blood pressure closely.Serum concentration for sedation: 0.5 to 3 mcg/mL.